Gilead looks to 'redefine' HIV PrEP market with 2025 launch of long-acting Sunlenca
Fierce Pharma
AUGUST 9, 2024
With Gilead's stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. | The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.
Let's personalize your content